Q2 2026 Ligand Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Royalty revenue increased 32% year-over-year and adjusted EPS grew 48% in Q2 2026, driven by strong performance from key products like Filspari, Otuber, and Zilsubme.
- The Zoma Royalty acquisition closed, adding over 120 assets, including 7 commercial-stage programs and 14 late-stage clinical programs, significantly diversifying the portfolio and extending royalty duration through 2040.
- The $700 million zero-coupon convertible offering provides low-cost capital with a call spread to limit dilution, strengthening the balance sheet and enabling continued business development.
- Zoma integration is on track to capture cost synergies, reducing annual operating expenses from ~$30 million to less than $5 million, and includes over $110 million in tax credits and NOLs for cash tax savings.
- The portfolio is entering a catalyst-rich period with up to 7 pivotal trial readouts and potential FDA approvals over the next 18 months, including Vabizmo, Ojemda, and Kutorin-rapamycin, which could drive significant future royalty growth.
- Amgen's Kyralis net sales decreased 17% year-over-year due to lower volume, partially offsetting growth from other products, though it remains within guidance.
- The Zoma acquisition includes financial royalty assets with complex accounting, where milestone payments may not be fully recognized as revenue, potentially reducing reported earnings transparency.
- The FDA recommended a Phase 3 trial for Volixibat in PSC, delaying potential approval and pushing back the timeline for this asset, despite positive Phase 2B data.
- The company incurred a $12 million one-time charge related to the Orchestra Bio investment, which, while excluded from adjusted earnings, reflects the immediate expensing of certain R&D financing transactions.
- The business development pipeline remains highly active, but the company faces inherent binary risks in clinical development, as not all pivotal studies are expected to be positive, which could impact future royalty streams.
Hello everyone. Thank you for joining us and welcome to the Ligand second quarter 2026 earnings call. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again.
I will now hand the conference over to Melanie Herman, Head of Investor Relations. Melanie, please go ahead.
Good morning, everyone, and welcome to Ligand's second quarter 2026 earnings call. With me on the call today are CEO, Todd Davis, Chief Financial Officer, Tabo Espinoza, and Vice President of Portfolio Strategy and Investments, Lauren Hay.
During the call today, we will review the financial results released earlier today and provide commentary on our partner portfolio and business development activity, followed by a question-and-answer session. Before we get started, I would like to point out we will be discussing non-GAAP results, which exclude certain items such
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
